Table 1.
Demographic and disease-related characteristics of IBD patients treated with thiopurine and allopurinol.
| Treatment indication | ||
|---|---|---|
| Abnormal metabolism group |
Thiopurine failure group |
|
| Gender M:F | 6:10 | 17:33 |
| CD (n) | 14 | 34 |
| L1 ± L4, n (%) | 2 (12) | 25 (50) |
| L2 ± L4, n (%) | 7 (44) | 5 (10) |
| L3 ± L4, n (%) | 7 (44) | 20 (40) |
| B1, n (%) | 11 (69) | 9 (39) |
| B2, n (%) | 4 (25) | 26 (52) |
| B3, n (%) | 1 (6) | 2 (9) |
| perianal, n (%) | 3 (19) | 7 (14) |
| UC (n) | 2 | 16 |
| E2, n (%) | 0 | 7 (44) |
| E3, n (%) | 2 (100) | 9 (56) |
| Previous bowel surgery, n (%) | 1 (6) | 11 (22) |
| Age at diagnosis (median in year) | 13 | 27 |
| Age when thiopurine started (median in year) | 15 | 34 |
| Age when allopurinol added (median in year) | 16.5 | 41 |
| Allopurinol dose, mg (mean) | 72.5 | 98,4 |
| Concomitant medications | ||
| Corticosteroid n = (%) | 0 (0) | 26 (52) |
| 5-ASA n = (%) | 5 (31) | 5 (10) |
| Anti-TNF n = (%) | 2 (12) | 7 (14) |
5-ASA, 5-aminosalicylic acid; anti-TNF, anti-tumor necrosis factor; CD, Crohn’s disease; UC, ulcerative colitis.